about
PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular LymphomasChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)Minimal Residual Disease Assessment in the Context of Multiple Myeloma TreatmentMicrobiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell TransplantationCARs in chronic lymphocytic leukemia -- ready to driveImmune reconstitution in chronic lymphocytic leukemiaChemotherapy only in early-stage Hodgkin lymphoma: more relapses but "same" (or possibly worse) survival--reconsidering the misguided trend to omit radiotherapySignal transduction in the chronic leukemias: implications for targeted therapiesRole of Microenvironment in Resistance to Therapy in AMLThe Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential ThrombocythemiaTransient Abnormal Myelopoiesis and AML in Down Syndrome: an UpdateIdentification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare ProviderLymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processesMyelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?10 Years of Preparedness by the Radiation Injury Treatment Network.Enteropathy-Associated T-Cell Lymphoma.T-cell Lymphoma Epidemiology: the Known and Unknown.Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.New Therapeutic Strategies in Acute Lymphocytic Leukemia.The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.New drugs for the treatment of myelofibrosis.Management of myelodysplastic syndromes in the geriatric patient.Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsMolecular Testing in Patients with Suspected Myelodysplastic Syndromes.A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.Selecting the best frontline treatment in chronic myeloid leukemiaBruton's tyrosine kinase (BTK) inhibitors in clinical trials.Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.Richter's transformation in chronic lymphocytic leukemia.Primary eosinophilic disorders: a concise review.Prognostic markers in peripheral T-cell lymphoma
P1433
Q26752284-48D9ECD0-A47B-4556-9F0F-482284FF4655Q26764833-99C66EDE-B962-4DBA-A597-90619DC4E0F2Q26768154-EE62C447-A902-4521-8EF4-3FE2680BB670Q26768653-2B52C91E-C963-4C5B-9B52-F7633E6736FAQ26771287-71A6BFB3-5273-4056-AA90-D59047060378Q26830526-6C4B96A3-89EE-475B-9AB3-A545AD058098Q26865561-ACF65A3C-D625-4013-BC79-09BD9474F45DQ27015790-E5A75567-8BDB-4A59-B2E0-D1DB1E155625Q27026031-4487602A-0E71-4469-8A28-9DAB54F572ABQ27027502-4D306602-0E24-4976-85CE-1982C6D00D6AQ28074777-3428AF59-AAB2-4A8B-8AE4-D48316137E98Q28079980-5C67AC8C-1ED2-4A08-9FA7-F0075A9B2E28Q28080914-E92B68B5-FD24-4116-8C47-1A9CA69F271FQ28081808-A0FD4259-8240-4288-B3B5-5C2CABC27F41Q28271456-B22D8AD9-BB8B-4A0D-A181-B3C6BD2E64B9Q28387115-B2F005C0-85EC-46C0-B8A7-361E5D29BC18Q30151400-37C9B0C2-3CB1-40DD-88AE-E98EA5048F81Q30239728-8BB7A50C-BC42-4270-8330-305B643D0B71Q30239985-6C5D5AEE-A559-4A9C-8969-3F254E505632Q30244110-810FDB2C-E543-4E59-9EE8-E73B85BB2106Q30251555-95F7B755-2562-4D51-AD9C-AE03A0CFC010Q30252776-5899378B-7207-4B34-AB03-7CE28FA1C3C0Q30278553-61CC1B4B-721C-4A52-B5A4-40A3F98403C7Q30964688-A71EAEAD-9922-4000-A9EC-B27DC4D81D44Q31095966-47F04502-39DF-4D38-872D-2B2654010EC6Q33389328-A28C9123-D78A-48C1-8269-7CAAF4D98D9BQ33389330-A7E7ABC6-4CA6-4DFC-B017-8CB10B5A90EEQ33389333-BAC95DE1-C318-4875-A8D3-A4F495A915F2Q33389335-0CC4FE86-8823-41B1-923A-4590E776EBFFQ33417217-FC91AF5F-B2EA-4F24-BE7E-0896359FC0E7Q33435980-CF09DF3A-6F99-4F66-AC3F-DC024DA52D54Q33439333-A95DB4F9-350D-4B8B-AE1A-894C4C74A348Q33764253-9AB84B9E-07F0-447E-BCF5-F659CE25A5EAQ34039406-8779D253-ADB3-4AE4-BE79-8E1154654D3BQ34047259-86921D73-B36F-445E-B26A-62A2028D7F7FQ34049017-A630E3F0-CF73-4E0A-BDED-C1594D2B4A43Q34112611-0322C200-38FD-4B3E-A97C-7FF33F48609FQ34112617-BC7BD2A8-B4B5-4798-B3A5-E09518ECF1EEQ34112623-F831B303-1309-4B0B-AFD1-7013876334AEQ34166857-3634CFF5-4CDE-4CD7-8870-9E964FEB6186
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Springer Science+Business Media
@nl
wissenschaftliche Fachzeitschrift
@de
name
Current hematologic malignancy reports
@ast
Current hematologic malignancy reports
@en
Current hematologic malignancy reports
@es
Current hematologic malignancy reports
@it
Current hematologic malignancy reports
@nl
type
label
Current hematologic malignancy reports
@ast
Current hematologic malignancy reports
@en
Current hematologic malignancy reports
@es
Current hematologic malignancy reports
@it
Current hematologic malignancy reports
@nl
prefLabel
Current hematologic malignancy reports
@ast
Current hematologic malignancy reports
@en
Current hematologic malignancy reports
@es
Current hematologic malignancy reports
@it
Current hematologic malignancy reports
@nl
P3181
P1055
P1156
5000156906
P1277
P1476
Current hematologic malignancy reports
@en